Published in Drug Metab Dispos on July 21, 2004
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics (2013) 1.19
Carboxylesterase inhibitors. Expert Opin Ther Pat (2011) 1.06
Examination of the carboxylesterase phenotype in human liver. Arch Biochem Biophys (2012) 1.01
Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin. Br J Pharmacol (2010) 1.00
Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity. J Med Chem (2009) 0.97
Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity. Mol Cancer Ther (2011) 0.87
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases. J Med Chem (2006) 0.86
Mammalian carboxylesterase 5: comparative biochemistry and genomics. Comp Biochem Physiol Part D Genomics Proteomics (2008) 0.85
A new class of mammalian carboxylesterase CES6. Comp Biochem Physiol Part D Genomics Proteomics (2009) 0.80
The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme. Molecules (2012) 0.78
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Invest New Drugs (2006) 0.77
A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos (2015) 0.77
Bovine Carboxylesterases: Evidence for Two CES1 and Five Families of CES Genes on Chromosome 18. Comp Biochem Physiol Part D Genomics Proteomics (2009) 0.77
Horse carboxylesterases: evidence for six CES1 and four families of CES genes on chromosome 3. Comp Biochem Physiol Part D Genomics Proteomics (2008) 0.77
Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology. Pharm Res (2014) 0.77
N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU. Cancer Chemother Pharmacol (2009) 0.77
Human α/β hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. J Biol Chem (2012) 0.75
Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases. J Pharm Sci (2016) 0.75
Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol (2004) 2.47
Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett (2004) 2.17
MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res (2006) 2.16
Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos (2008) 2.02
Analysis of fungi detected in human cadavers. Leg Med (Tokyo) (2006) 1.97
Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem (2008) 1.84
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther (2006) 1.82
High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol (2006) 1.63
Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif (2002) 1.46
Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther (2002) 1.45
Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res (2004) 1.45
MicroRNA regulates human vitamin D receptor. Int J Cancer (2009) 1.43
Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome (2010) 1.40
MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle. J Biol Chem (2009) 1.37
Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos (2009) 1.34
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci (2007) 1.31
Human CYP2E1 is regulated by miR-378. Biochem Pharmacol (2009) 1.25
Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos (2007) 1.24
Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. Chem Res Toxicol (2008) 1.21
Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol (2009) 1.18
Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet (2004) 1.14
Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet (2005) 1.14
PPARα is regulated by miR-21 and miR-27b in human liver. Pharm Res (2011) 1.12
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics (2007) 1.08
Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics (2008) 1.07
microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol (2012) 1.07
Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch Toxicol (2002) 1.05
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther (2004) 1.04
Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci (2004) 1.04
Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol (2011) 1.03
Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos (2004) 1.03
Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. Toxicol Lett (2003) 1.03
The emerging role of human esterases. Drug Metab Pharmacokinet (2012) 1.01
Chimeric mice with humanized liver. Toxicology (2007) 1.01
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther (2003) 0.99
CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos (2005) 0.99
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS One (2012) 0.98
Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes. Drug Metab Dispos (2004) 0.98
Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci (2007) 0.98
Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos (2007) 0.98
CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer (2006) 0.97
Toxicological implications of modulation of gene expression by microRNAs. Toxicol Sci (2011) 0.97
Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci (2006) 0.96
Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. Toxicol Sci (2005) 0.96
Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J Pharm Sci (2007) 0.95
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol (2005) 0.95
MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. Pharmacol Ther (2011) 0.95
Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos (2003) 0.94
Different inhibitory effects in rat and human carboxylesterases. Drug Metab Dispos (2009) 0.94
Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. Am J Physiol Gastrointest Liver Physiol (2006) 0.94
Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem Pharmacol (2010) 0.94
Knock down of gamma-glutamylcysteine synthetase in rat causes acetaminophen-induced hepatotoxicity. J Biol Chem (2007) 0.94
A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics (2004) 0.93